<DOC>
	<DOCNO>NCT01181024</DOCNO>
	<brief_summary>This randomize , double-blind , placebo control , 3 part study ass safety , tolerability pharmacokinetics RO5303253 healthy volunteer patient chronic hepatitis C genotype 1 . In Part A , cohorts healthy volunteer randomize receive single ascending dos RO5303253 placebo . In Part 2 , healthy volunteer receive single dose RO5303253 placebo cross-over design ( washout period least 7 day ) assess food effect pharmacokinetics . In Part 3 , patient chronic hepatitis C randomize ro receive either RO5303253 placebo 5 day .</brief_summary>
	<brief_title>A Study Safety , Tolerability Pharmacokinetics RO5303253 Healthy Volunteers Patients With Chronic Hepatitis C Genotype 1</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Healthy volunteer patient chronic hepatitis C genotype 1 , 18 60 year age Patients must treatmentna√Øve antiviral therapy chronic hepatitis C interferon base therapy Body mass index ( BMI ) 18 32 kg/m2 inclusive , minimum weight 45 kg Females must surgically sterile menopausal Male subject partner childbearing potential must use 2 method contraception throughout study 70 day last dose Pregnant lactate woman male partner woman pregnant lactate Women reproductive potential Positive hepatitis B HIV ( hepatitis C healthy volunteer ) screen For hepatitis C patient : decompensated liver disease impair liver function , evidence cirrhosis document time , presence history nonhepatitis C chronic liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>